A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
Ipratropium bromide nasal solution 0.06% is indicated for symptomatic relief of rhinorrhea associated with the common cold or ...
Confusion between approved injectable epinephrine products and unapproved nasal solutions has prompted a warning to ...
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback